acccecccefc

Sarah Collins

Contact us by Email

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Sarah Collins

  • uploads///consumer health market
    Company & Industry Overviews

    Could Pfizer and P&G agree on a Consumer Health Business Deal?

    Pfizer (PFE) has been looking to sell its consumer health business since October 2017.

    By Sarah Collins
  • uploads///eps
    Earnings Report

    What to Expect from St. Jude Medical’s Earnings in 2Q16

    In 1Q16, St. Jude Medical exceeded analysts’ EPS (earnings per share) estimate of $0.89 as well as the revenue estimate of ~$1.4 billion.

    By Sarah Collins
  • uploads///Q EPS
    Earnings Report

    Weighing in with Boston Scientific’s 4Q15 Revenues

    Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    How Long Will Stryker Stock Sustain Its Bullish Trend?

    Stryker (SYK) closed at $145.4 on July 18, 2017. It has a 50-day moving average of $141.8 and a 200-day moving average of $132.6.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Becton, Dickinson and Company’s 4Q16 Earnings Estimates

    Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    How Does UNH’s Valuation Look in October?

    UnitedHealth Group is a leading managed healthcare firm in the United States.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Will Medtronic Maintain Its Revenue Growth Momentum in Fiscal 1Q18?

    In fiscal 1Q18, Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.45 billion, which represents a rise of ~4% in comparison to its fiscal 1Q17 revenue of $7.17 billion.

    By Sarah Collins
  • uploads///REVENUE ESTIMATES
    Earnings Report

    Analysts Expect Medtronic’s Revenue to Rise 4% in Fiscal 4Q17

    Wall Street analysts expect Medtronic’s (MDT) revenue to be ~$7.9 billion in fiscal 4Q17, a rise of ~4% compared to its fiscal 4Q16 revenue of $7.6 billion.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Teva Stock Has Risen Significantly since November Lows: What’s Next?

    On January 5, 2018, Teva Pharmaceuticals (TEVA) closed at $19.2 per share, which was ~77% higher than its 52-week low of $10.8 reported on November 2, 2017.

    By Sarah Collins
  • uploads///STOCK PRICE
    Earnings Report

    How Has Medtronic’s Stock Performed Recently?

    Medtronic (MDT) was trading at $80.3 on November 15, 2016. It had a 50-day moving average of $83.7 and a 200-day moving average of $84.8.

    By Sarah Collins
  • uploads///epipen
    Earnings Report

    Mylan’s EpiPen Supply Shortages Continue: What to Expect Ahead

    During its second-quarter earnings release on August 8, Mylan provided an update on its EpiPen supply shortages.

    By Sarah Collins
  • uploads///recommendations
    Company & Industry Overviews

    What Wall Street Analysts Recommend for Dentsply Sirona

    Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

    By Sarah Collins
  • uploads///the device _
    Company & Industry Overviews

    JNJ’s Medical Devices Growth Plans amid Changing Market Dynamics

    Johnson & Johnson (JNJ) has been working on changing its business model.

    By Sarah Collins
  • uploads///ORAL CARE
    Company & Industry Overviews

    Johnson & Johnson Is Reinventing Its Oral Care Franchise

    Johnson & Johnson’s (JNJ) oral care business registered an operational sales decline of 3.2% in fiscal 2017.

    By Sarah Collins
  • uploads///WILSON DISEASE
    Healthcare

    Wilson Disease: A Market Opportunity for Alexion

    Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    How Hologic’s Valuation Stacks Up with Peers

    The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

    By Sarah Collins
  • uploads///kyle sterk  unsplash
    Company & Industry Overviews

    ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain

    On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump

    Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.

    By Sarah Collins
  • uploads///revenue estimates
    Earnings Report

    Medtronic’s Revenue Is Estimated to Rise in Fiscal 2Q17

    On November 22, 2016, Medtronic (MDT) will announce its fiscal 2Q17 earnings for the period that ended on October 31, 2016.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Zimmer Biomet Stock Regains Momentum: What’s Driving Growth?

    Ximmer Biomet (ZBH) has risen 2.1% since its 1Q17 earnings release on April 27, 2017. The results exceeded analysts’ estimates, but ZBH lowered its 2017 guidance.

    By Sarah Collins
  • uploads///computer _
    Company & Industry Overviews

    Boston Scientific Stock Up Today on the Acquisition of Veniti

    Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///pill _
    Company & Industry Overviews

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) stock fell ~9% on news regarding its drug Baricitinib, which is under FDA review.

    By Sarah Collins
  • uploads///medicine _
    Company & Industry Overviews

    Mylan Launches First Adcirca Generic, Stock Moves Up

    Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States.

    By Sarah Collins
  • uploads///capital plan
    Company & Industry Overviews

    UnitedHealth Group Goes Ex-Dividend Today

    UnitedHealth Group (UNH) has announced that its board of directors has authorized a cash dividend of $0.90 per share.

    By Sarah Collins
  • uploads///animas exit from insulin pump business
    Company & Industry Overviews

    Tandem Diabetes Care’s International Expansion Strategy

    Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Discussing Analysts’ Latest Recommendations on VAR Stock

    Varian Medical Systems (VAR) is a better-aligned, leaner business with a strong market position after the spin-off of Varex Imaging (VREX) in January 2017.

    By Sarah Collins
  • uploads///piron guillaume  unsplash
    Earnings Report

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Berkshire Hathaway Increased Its Stake in Teva Again

    Teva stock has gained ~27.0% year-to-date on the back of the positive news that included product launches and study data.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Why Alnylam Pharmaceuticals Stock Rose ~16% Yesterday

    Yesterday, Alnylam Pharmaceuticals (ALNY) closed the day ~16.3% higher than the previous day’s closing price.

    By Sarah Collins
  • uploads///DIABETES
    Earnings Report

    What Really Disrupted Medtronic’s Diabetes Segment Sales in Fiscal 2Q17?

    Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

    By Sarah Collins
  • uploads///dna _
    Earnings Report

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

    By Sarah Collins
  • uploads///family _
    Company & Industry Overviews

    UNH’s Stock Price Performance in June

    On June 28, UnitedHealth Group (UNH) ended the trading day at $244.90, ~4.6% lower than its 52-week low of $183.86 reached on July 18, 2017.

    By Sarah Collins
  • uploads///segment revenues
    Company & Industry Overviews

    How Will the Lotus Recall Affect BSX’s 2017 Performance?

    Boston Scientific has begun implementing the necessary fixes for its Lotus Valve system, and it expects to relaunch the product in the Europe and other international markets in 4Q17.

    By Sarah Collins
  • uploads///valuation
    Company & Industry Overviews

    Investor Insights: Teva Pharmaceutical’s Valuation Multiples

    On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x.

    By Sarah Collins
  • uploads///CASH FLOW
    Company & Industry Overviews

    How Tax Reform Affected Medtronic’s 3Q18 Performance

    Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

    By Sarah Collins
  • uploads///hospital _
    Company & Industry Overviews

    A Look at Hologic Stock’s Recent Performance

    Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

    By Sarah Collins
  • uploads///minimed g launch dynamics
    Company & Industry Overviews

    Diabetes Management Breakthrough: Medtronic’s MiniMed 670G

    On June 7, 2017, Medtronic (MDT) announced the launch of MiniMed 670G—the world’s first HCL (hybrid closed loop) insulin delivery system.

    By Sarah Collins
  • uploads///addiction _
    Company & Industry Overviews

    Sanofi, Adaptive Biotechnologies Plan Multiple Myeloma Trials

    On May 29, Adaptive Technologies and Sanofi (SNY) formed a collaboration for a multiple myeloma trial.

    By Sarah Collins
  • uploads///diabetes _
    Company & Industry Overviews

    Why Senseonics Holdings Is Up ~5.6% Today

    Today, Senseonics Holdings (SENS) is trading higher than yesterday’s close of $4.43 per share. The stock was up ~5% in premarket trading and is trending higher since then.

    By Sarah Collins
  • uploads///segment wise performance
    Earnings Report

    Will Pharmaceuticals Keep Fueling J&J’s Performance in Q2 2018?

    The majority of Johnson & Johnson’s sales come from its pharmaceuticals division. The company also operates across medical devices and consumer business segments.

    By Sarah Collins
  • uploads///CARDIOVASCULAR revenues
    Company & Industry Overviews

    Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?

    In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.

    By Sarah Collins
  • uploads///aid __
    Company & Industry Overviews

    Boston Scientific Expands Its Endoscopy Business with EMcision Acquisition

    On March 5, 2018, Boston Scientific (BSX) announced the acquisition of EMcision, which will expand the company’s endoscopy business.

    By Sarah Collins
  • uploads///women health
    Company & Industry Overviews

    How Johnson & Johnson Plans to Restore Women’s Health Sales

    Johnson & Johnson (JNJ) reported sales of $3.4 billion in its consumer business in the first quarter, with 7% of it from its women’s health business.

    By Sarah Collins
  • uploads///minimed g
    Company & Industry Overviews

    Medtronic’s Key Growth Driver: MiniMed 670G Hybrid Closed Loop

    Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.

    By Sarah Collins
  • uploads///ocrevus
    Company & Industry Overviews

    Why NICE Didn’t Approve Roche’s Ocrevus for Multiple Sclerosis

    On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.

    By Sarah Collins
  • uploads///tablets _
    Earnings Report

    Teva Stock Rises on Strong 1Q18 Results, Outlook Up

    Today, Teva Pharmaceutical Industries (TEVA) released its 1Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///omnichannel presence
    Company & Industry Overviews

    Johnson & Johnson’s Growth Strategy: Expand Emerging Channels

    Amid the increasing presence of digital technology, Johnson & Johnson (JNJ) has recognized the need to expand its channel presence.

    By Sarah Collins
  • uploads///thv
    Earnings Report

    What Led to Edwards Lifesciences’ Stellar Performance in 1Q16?

    Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$366 million was contributed by the company’s THV (Transcatheter Heart Valve) Therapy segment.

    By Sarah Collins
  • uploads///syringe pill capsule morphine
    Earnings Report

    Seattle Genetics Posted Strong Q2 2018 Results, Stock Rose

    Seattle Genetics reported sales of $170.2 million in the second quarter, which represented 57.2% growth YoY (year-over-year).

    By Sarah Collins
  • uploads///attractive product profile
    Company & Industry Overviews

    What’s behind Biogen Buyout Rumors?

    Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

    By Sarah Collins
  • uploads///HALCYON
    Company & Industry Overviews

    Varian’s Halcyon Treatment System Sees Emerging Market Demand

    Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]

    By Sarah Collins
  • uploads///share price on Oct
    Earnings Report

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close.

    By Sarah Collins
  • uploads///oncology
    Company & Industry Overviews

    TMO’s Oncomine Target Test Launch Will Boost This Business

    On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Earnings Report

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences is set to release its third-quarter earnings results after the market closes on October 23. Let’s see what to expect.

    By Sarah Collins
  • uploads///OTC
    Company & Industry Overviews

    Johnson & Johnson’s Over-the-Counter Growth through Innovation

    In its fiscal first quarter, Johnson & Johnson (JNJ) registered sales of $1.1 billion for its OTC (over-the-counter) business.

    By Sarah Collins
  • uploads///core strategies
    Company & Industry Overviews

    How Are Stryker’s Core Strategies Working Toward Its Growth?

    Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

    By Sarah Collins
  • uploads///blood pressure monitor _
    Company & Industry Overviews

    Medtronic: Wall Street’s Views and Latest Recommendations

    On May 31, Medtronic had a consensus 12-month target price of $93.81, implying a 12-month investment return potential of ~9.2%.

    By Sarah Collins
  • uploads///syringe _
    Company & Industry Overviews

    Teva’s Granix Gets FDA Approval for Expanded Indication

    Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

    By Sarah Collins
  • uploads///drug _
    Earnings Report

    Analysts’ Recommendations for Sanofi Stock before Q2 Results

    Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.

    By Sarah Collins
  • uploads///diabetes _
    Earnings Report

    Analysts’ Recent Recommendations and Target Price for ABT Stock

    On May 2, a Reuters survey noted that of 20 brokerage firms tracking Abbott Laboratories, 16 analysts recommended a “buy” or a “strong buy.”

    By Sarah Collins
  • uploads///red blood cells _
    Company & Industry Overviews

    Why Sellas Life Sciences Stock Rose over 11% Today

    Today, Sellas Life Sciences (SLS) announced that the FDA has assigned fast-track designation to its lead drug, GPS (galinpepimut-S), which is under development for the treatment of multiple myeloma.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    BD’s Stock Price Performance after Recent 52-Week High

    On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

    By Sarah Collins
  • uploads///pharma
    Earnings Report

    Oncology Portfolio Sales Drove J&J’s Pharmaceuticals Business

    Johnson & Johnson (JNJ) reported Pharmaceuticals segment sales of $10.4 billion in Q2 2018 during its earnings release on July 17.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Will Medtronic Meet Analysts’ Earnings Estimates in Fiscal 1Q18?

    For the last several quarters, Medtronic has consistently exceeded analysts’ earnings estimates.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Align Technology Traded at Its 52-Week High in September

    Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.

    By Sarah Collins
  • uploads///anatomy _
    Company & Industry Overviews

    What Triggered a 52-Week High for Boston Scientific in October?

    On October 2, Morgan Stanley raised its target price for BSX stock. That day, BSX stock was trading at its 52-week high.

    By Sarah Collins
  • uploads///CURRENT TREATMENT LIMITATIONS
    Healthcare

    WTX101: A Superior Treatment for Wilson Disease

    WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Tandem Diabetes Care’s Stock Performance This Month

    On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.

    By Sarah Collins
  • uploads///doctor medical medicine health
    Earnings Report

    Boston Scientific’s 1Q18 Results: Key Highlights

    Yesterday, Boston Scientific released its 1Q18 earnings results. The company registered sales of $2.38 billion.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.

    By Sarah Collins
  • uploads///aid _
    Company & Industry Overviews

    CVS Health Launches Prescription Delivery Service, Stock Jumps ~5%

    Today, CVS Health, the leading pharmacy benefit managers, is up ~5% after announcing the launch of its drug delivery service from all of its US locations.

    By Sarah Collins
  • uploads///rawpixel  unsplash
    Earnings Report

    UNH Stock Up 4.1% on Solid Q3 2018 Results, View Up

    UnitedHealth Group (UNH) released its Q3 2018 earnings today. UNH reported sales of $56.6 billion, up ~12.4% on a year-over-year basis.

    By Sarah Collins
  • uploads///brain _
    Company & Industry Overviews

    IsoRay Stock Jumps 160% on FDA Clearance for Brain Tumor Therapy

    Today, IsoRay Inc. (ISR) stock rallied ~160% and closed trading at $1.14, compared to its previous closing price of $0.44.

    By Sarah Collins
  • uploads///cancer _
    Company & Industry Overviews

    Tesaro Stock Up over 16% on Rumors of Acquisition by Roche

    Yesterday, Tesaro (TSRO) stock rose ~16.3%, triggered by rumours of an acquisition bid by Roche (RHHBY), which registered a stock price rise of ~2.1%.

    By Sarah Collins
  • uploads///ken treloar  unsplash
    Earnings Report

    Hologic Stock Falls Over 9% on 2Q18 Results, Lower 2018 Guidance

    Yesterday, after the market closed, Hologic (HOLX) released its 2Q18 earnings results for the quarter that ended on March 31.

    By Sarah Collins
  • uploads///DIABETES
    Company & Industry Overviews

    Johnson & Johnson Gets FDA Approval for Type 2 Diabetes Drug

    On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Wall Street Analysts Are Still Bullish on ALGN Stock

    Align Technology (ALGN) stock hasn’t received any recommendation updates since the stock was upgraded by several analysts in July.

    By Sarah Collins
  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///approved _
    Company & Industry Overviews

    FDA Approves Teva’s Generic Version of EpiPen, Stock Up 7.5%

    Teva Pharmaceutical Industries (TEVA) received FDA approval for the generic version of Mylan’s (MYL) allergy products EpiPen and EpiPen Jr.

    By Sarah Collins
  • uploads///specialty products pipeline
    Company & Industry Overviews

    Non-Opioid Pain Therapy Market Opportunity for Teva

    The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

    By Sarah Collins
  • uploads///stock performance
    Earnings Report

    Abbott Laboratories’ Stock Price Performance in July

    Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

    By Sarah Collins
  • uploads///recommendation
    Company & Industry Overviews

    Jefferies Raised Its Target Price on UNH Stock: What’s the Outlook?

    UnitedHealth Group (UNH) is one of the largest Fortune 500 companies.

    By Sarah Collins
  • uploads///GSK CONSUMER HEALTHCARE MILESTONES
    Company & Industry Overviews

    GlaxoSmithKline Buys Novartis’s Stake in Joint Venture

    On March 27, 2018, GlaxoSmithKline (GSK) announced an agreement with Novartis (NVS) to buy Novartis’s stake in their consumer healthcare joint venture.

    By Sarah Collins
  • uploads///hush naidoo  unsplash
    Company & Industry Overviews

    Trade War Fears Triggered Medtronic’s Stock Decline on March 23

    Following heightened concerns of a US–China trade war, Medtronic (MDT) stock hit its 52-week low of $76.41 on March 23, 2018.

    By Sarah Collins
  • uploads///erleada
    Company & Industry Overviews

    Johnson & Johnson’s Erleada Approved by Health Canada

    On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada.

    By Sarah Collins
  • uploads///mitg segment performance
    Company & Industry Overviews

    Innovative Products Driving Medtronic’s Growth

    Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.

    By Sarah Collins
  • uploads///pill _
    Earnings Report

    What Analysts Recommend for Mylan before Q2 2018 Earnings

    Mylan (MYL) plans to release its Q2 results on August 8. Thirteen of the 20 analysts covering the stock have given it a “buy” or “strong buy.”

    By Sarah Collins
  • uploads///syringe _
    Company & Industry Overviews

    Johnson & Johnson in the Changing Consumer Market Landscape

    Although changing consumer market dynamics pose challenges for Johnson & Johnson (JNJ), it’s confident it will be able to adapt.

    By Sarah Collins
  • uploads///Part
    Company & Industry Overviews

    Wall Street Looks at Sales Forecasts for Mylan’s Fulphila

    According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.

    By Sarah Collins
  • uploads///Part
    Company & Industry Overviews

    Mylan’s Biosimilar of Neulasta Expected to Be a Key Growth Driver

    Mylan (MYL) received FDA approval for Fulphila in June, and the drug was launched in the United States in July.

    By Sarah Collins
  • uploads///pill _
    Company & Industry Overviews

    Sanofi Stock: How Much Upside Potential Does Wall Street See?

    In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    How Has Boston Scientific Stock Performed Recently?

    Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Will Dentsply Sirona Stock Recover from Recent Declines?

    On April 6, 2018, Dentsply Sirona (XRAY) ended at a closing price of $49.02 per share.

    By Sarah Collins
  • uploads///innovation strategies
    Company & Industry Overviews

    How Johnson & Johnson’s Partnerships Enhance Customer Value

    Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

    By Sarah Collins
  • uploads///darzalex
    Company & Industry Overviews

    Johnson & Johnson Seeks EU and US Label Expansion for Darzalex

    Johnson & Johnson’s (JNJ) subsidiary Janssen Pharmaceuticals filed regulatory submissions for label expansion of its multiple myeloma drug Darzalex.

    By Sarah Collins
  • uploads///recommendations
    Earnings Report

    Analyst Recommendations for Varian Medical Systems before 1Q18

    Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.

    By Sarah Collins
  • uploads///Part
    Company & Industry Overviews

    Mylan’s Humira Biosimilar Opportunity in Europe

    On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

    By Sarah Collins
  • uploads///hospital _
    Earnings Report

    Analysts’ Views on Abbott Laboratories before Q2 2018 Earnings

    On July 18, Abbott Laboratories (ABT) is expected to release its earnings results for its fiscal second quarter of 2018.

    By Sarah Collins
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.